Pernix Therapeutics Holdings (PTX) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts PTX Hot Sheet
Join SI Premium – FREE
Pernix Therapeutics Holdings (NYSE: PTX) reported Q2 EPS of $0.07, $0.04 better than the analyst estimate of $0.03. Revenue for the quarter came in at $12 million versus the consensus estimate of $7.11 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Epsilon Energy Ltd. (EPSN) Reports Q2 EPS of $0.23
- CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
